GlassScriptPhysician profile
Christopher W Davis
NPI 1477298503
$993.76
in general payments reported to CMS, 2019-2025
14 companies · $364 in 2025
The $364 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $261 · 2024: $369 · 2025: $364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $986 · Education: $7.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $985.80 |
| Education | $7.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $351.97 | 2023-2024 | Krystexxa, Repatha, Aimovig |
| Abbvie INC. | $180.73 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $134.08 | 2024-2025 | Tezspire, Breztri |
| Hologic Sales and Service, LLC | $105.52 | 2025 | Aptima |
| Exact Sciences Corporation | $37.05 | 2025 | Cologuard Collection Kit |
| Pulmonx Corporation | $31.31 | 2025 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Mallinckrodt Hospital Products INC. | $27.25 | 2025 | Acthar |
| Bayer Healthcare Pharmaceuticals INC. | $21.53 | 2025 | |
| Merck Sharp & Dohme LLC | $19.61 | 2025 | Vaxneuvance, Enflonsia, Rotateq |
| Dexcom, INC. | $18.89 | 2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $18.43 | 2023 | Arexvy |
| Pfizer INC. | $16.53 | 2023 | |
| Axsome Therapeutics, INC. | $15.92 | 2023 | Auvelity |
| Ars Pharmaceuticals Operations, INC. | $14.94 | 2025 | Neffy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.